☏ +1 650 501 5505 ✉ [email protected]
Drug Pipeline Review Therapy area: Parkinson's Disease40–50 pages · PDF + Excel tracker

Parkinson’s Disease Drug Pipeline: 106 Assets by Phase

Parkinson's Disease pipeline: 106 drug candidates in clinical development, 14 in Phase III, from 87 sponsors. Data as of 8 Oct 2026.

Pipeline Terminal Parkinson's Disease Data as of 8 Oct 2026
Candidates in development 106assets Desk-reviewed How this number is madeEvery drug named in an interventional trial, merged across code, generic and brand names, with a live or recent industry trial. Placebo and comparator arms excluded.
Phase III 1413% of pipeline Registry How this number is madeCandidates whose highest phase in a live or recent trial is Phase III (Phase II/III counts as Phase II).
Phase II 4240% of pipeline Registry
Phase I 5047% of pipeline Registry
Sponsors 87top 5 hold 15% Registry How this number is madeCompanies credited with at least one candidate: the lead sponsor on most of that candidate's industry trials.
Registered trials 632205 running Registry How this number is madeInterventional trials on ClinicalTrials.gov for the conditions in scope, updated since 3 Oct 2021.
Readouts in 12 months 12Phase II or later Sponsor dates How this number is madeCandidates with a registered primary completion date in the next 12 months. Dates are the sponsor's own and often move.
Trials with US sites 31149% · Europe 28% Registry How this number is madeTrials with at least one site in the United States; Europe is the EU/EEA, the UK and Switzerland. A trial counts in every region where it has a site.

Candidates by highest phase reached

Phase I50
Phase II42
Phase III14

Next registered primary completions, Phase II or later

CandidatePhasePrimary completion
Levodopa/carbidopaPhase II/IIINov 2026 (est.)
TB006Phase IINov 2026 (est.)
Human Dopaminergic Progenitor CellsPhase IIDec 2026 (est.)

Candidates in development by lead sponsor

Prevail Therapeutics4
Shanghai Vitalgen BioPharma Co., Ltd.4
AbbVie3
Hoffmann-La Roche3
iCamuno Biotherapeutics Ltd.2

Phase II and III primary completions per quarter

Q4 20264
Q1 20272
Q2 20272
Q3 20273
Q4 20273
Q1 20282
Q2 20284
Q3 20281

Answers at a glance

  • 14 of 106 Parkinson's disease candidates (13%) are in Phase III.
  • Prevail Therapeutics runs the largest Parkinson's disease pipeline, with 4 candidates.
  • 12 readouts are due in 12 months; the next is Levodopa/carbidopa in Nov 2026.
  • 112 trials are recruiting patients now; 49% of all trials have a US site and 28% a European one.
106 candidates632 trials57 countriesData as of 8 Oct 2026Next refresh by 6 Jan 2027
USD 3,000Pipeline Snapshot Download Free Sample Request the Review
Edition: data as of 8 Oct 2026 Next refresh: by 6 Jan 2027 Change: First edition

Request a free sample

A sample of the Parkinson's Disease Pipeline Review: the full chapter list, the tracker columns and two asset profiles from the report. The Research Desk reviews your request and emails it, usually within one business day.

Parkinson's Disease has 106 drug candidates in active clinical development, of which 14 are in Phase III, 42 in Phase II and 50 in Phase I, according to Douglas Insights' count of 632 interventional trials registered on ClinicalTrials.gov (data as of 8 Oct 2026).

The Parkinson's disease drug pipeline is the set of medicines that sponsors are still testing in people for this condition: each candidate is counted once, at the highest phase it has reached in a running or recently completed trial. Medicines already on the market and studied only in Phase IV trials are kept out of the count.

How many Parkinson's disease drugs are in each phase of development?

Douglas Insights counts 14 Parkinson's disease candidates in Phase III, 13% of the 106 assets in development; Phase II holds 42 and Phase I holds 50.

Phase I50Phase II42Phase III14
Candidates by highest phase reached. Source: Douglas Insights from ClinicalTrials.gov, data as of 8 Oct 2026.
Phase (highest reached)AssetsShare of pipeline
Phase III1413%
Phase II4240%
Phase I5047%
Total106100%

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each Parkinson's disease asset appears in exactly one row. The 205 trials still recruiting or running carry 32% of the 632 registered trials in scope.

How many Parkinson's disease trials are recruiting patients now?

112 Parkinson's disease trials are recruiting patients and 50 more have not started recruiting yet, out of 632 interventional trials in scope; together they make up 26% of the trial base.

Registry statusTrialsShare
Completed30348%
Recruiting11218%
Status not verified568.9%
Not yet recruiting507.9%
Terminated406.3%
Active, not recruiting396.2%
Withdrawn243.8%
Enrolling by invitation40.6%
Suspended40.6%

Terminated, suspended and withdrawn Parkinson's disease trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the Parkinson's disease pipeline?

Prevail Therapeutics leads the Parkinson's disease pipeline with 4 candidates; the top 5 sponsors hold 15% of the 106 assets, and 87 sponsors run at least one.

SponsorAssets in developmentShare
Prevail Therapeutics43.8%
Shanghai Vitalgen BioPharma Co., Ltd.43.8%
AbbVie32.8%
Hoffmann-La Roche32.8%
iCamuno Biotherapeutics Ltd.21.9%

Industry sponsors lead 309 of the 632 Parkinson's disease trials (49%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the Parkinson's disease pipeline?

Mechanism and drug-type classification for the 106 Parkinson's disease candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What Parkinson's disease trial readouts are coming next?

12 Parkinson's disease candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

CandidateSponsorPhasePrimary completionRegistry
Levodopa/carbidopaAbbViePhase II/IIINov 2026 (estimated)NCT07229664
TB006TrueBinding, Inc.Phase IINov 2026 (estimated)NCT06773962
Human Dopaminergic Progenitor CellsiRegene Therapeutics Co., Ltd.Phase IIDec 2026 (estimated)NCT07028632

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many Parkinson's disease readouts fall in each quarter?

21 Parkinson's disease candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 4, due in Q4 2026.

QuarterPhase III readoutsPhase II readoutsTotal
Q4 2026044
Q1 2027112
Q2 2027022
Q3 2027033
Q4 2027123
Q1 2028112
Q2 2028044
Q3 2028011

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most Parkinson's disease trials?

United States hosts the most Parkinson's disease trials, with sites in 311 of the 632 studies (49%); trials in scope run in 57 countries in all.

CountryTrials with a siteShare of trials
United States31149%
China8013%
France6911%
United Kingdom619.7%
Germany589.2%
Spain589.2%
Italy528.2%
Canada477.4%

A multinational Parkinson's disease trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are Parkinson's disease drugs being tested?

311 of the 632 Parkinson's disease trials (49%) have a site in the United States, 174 (28%) in Europe and 80 (13%) in China; 53 of the 106 candidates in development are tested in the US.

RegionTrials with a siteShare of trialsCandidates testedRegulator
United States31149%53FDA
Europe (EU/EEA, UK, Switzerland)17428%35EMA, MHRA, Swissmedic
China8013%24NMPA
Japan203.2%7PMDA
Rest of world14022%31national regulators

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational Parkinson's disease trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the Parkinson's disease pipeline since the last update?

This is the first edition of the Parkinson's disease pipeline count, dated 8 Oct 2026. The next refresh is due by 6 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the Parkinson's disease pipeline?

Douglas Insights read 632 interventional trials registered on ClinicalTrials.gov for the conditions "parkinson disease" (excluding "neoplasms", "cancer", "carcinoma", "solid tumor") and updated since 3 Oct 2021, then grouped every drug or biologic named in them into 106 unique candidates.

  1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
  2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
  3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
  4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

What does the Parkinson's Disease Pipeline Review include?

The Parkinson's Disease Pipeline Review covers all 106 candidates in an Excel tracker and profiles the leading 25 in a 40–50 page report, ending with the research desk's ranked view of the candidates most likely to win.

11 chapters40–50 pages25 asset profilesExcel tracker of all 106 candidates
01Executive summary and our call2–3 pp

The pipeline on one page and the desk's verdict on where Parkinson's disease treatment is heading.

  • Pipeline size and phase mix
  • The three calls that matter
  • What changed since the last edition
02Disease and unmet need3 pp

Who is treated today, what current therapy leaves unmet, and how regulators judge new medicines.

  • Patient population and diagnosis
  • Treatment guidelines and gaps
  • Regulatory endpoints
03Approved therapies3 pp

The marketed medicines every Parkinson's disease candidate will be measured against.

  • Marketed medicines and their sponsors
  • Post-approval trials
  • The bar a new entrant must clear
04Pipeline at a glance4 pp

Every candidate counted by phase, drug type, sponsor and country.

  • Assets by phase and drug type
  • Sponsors by size of pipeline
  • Trial footprint: US, Europe, China, Japan
05Mechanism landscape and white space5 pp

Which mechanisms are crowded and which no sponsor has entered.

  • Mechanism classes and crowding
  • Classes with no candidate yet
  • Differentiation by route and dosing
06Key asset profiles12–15 pp

The leading 25 candidates, one profile each, every claim linked to a source document.

  • Design and endpoints of the pivotal trials
  • Data to date, with sources
  • Next readout and the risk to it
07Catalyst calendar3 pp

Readouts, filings and regulatory decisions 24 months ahead.

  • Readouts by quarter
  • Filings and regulatory decisions
  • Date confidence for each event
08Deals and partnering3 pp

Who is licensing, buying and partnering in Parkinson's disease, and on what terms.

  • Licensing and M&A in the area
  • Deal terms where disclosed
  • Sponsors open to partnering
09Sponsor landscape3 pp

Large pharma against biotech, and how concentrated the pipeline is.

  • Pipeline share by sponsor
  • Sponsor-by-phase matrix
  • New entrants since the last edition
10Our call: winners, risks, opportunities3–4 pp

The candidates most likely to win, ranked, with the reasoning and evidence.

  • Ranked candidates
  • Risks that could change the order
  • Openings for new entrants and investors
11Methodology and source log2 pp

How the count is built and every document behind it.

  • How candidates are counted and merged
  • Every source document listed
  • The ten quality checks

Ways to buy the Parkinson's Disease review

OptionWhat you getDeliveryPrice
Pipeline SnapshotThis therapy area as published: PDF report + Excel trackerReady nowUSD 3,000Enquire
Pipeline ReviewYour indication, geography and phase cut-off; ranked calls and an analyst call2–3 weeksFrom USD 4,000Enquire
Company AssessmentOne sponsor's full pipeline against its peers2 weeksFrom USD 5,000Enquire

Email me the sample and chapter listAsk for a quote

Frequently asked questions about the Parkinson's disease pipeline

How many drugs are in the Parkinson's disease pipeline?

106 drug candidates are in active clinical development for Parkinson's disease, with 14 in Phase III, per Douglas Insights (data as of 8 Oct 2026).

Which company has the most Parkinson's disease drugs in development?

4 candidates make Prevail Therapeutics the largest Parkinson's disease pipeline sponsor, out of 87 sponsors counted by Douglas Insights.

When is the next Parkinson's disease trial readout?

Nov 2026 is the registered primary completion of the Phase II/III trial of Levodopa/carbidopa (NCT07229664), the next Parkinson's disease catalyst in Douglas Insights' calendar.

How many Parkinson's disease trials run in the United States and Europe?

311 Parkinson's disease trials have a US site and 174 a European site, out of 632 registered trials counted by Douglas Insights (data as of 8 Oct 2026).

How often is the Parkinson's disease pipeline count updated?

90 days is the refresh cycle; this edition uses registry data as of 8 Oct 2026 and the next is due by 6 Jan 2027.

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Cite this page Douglas Insights (2026). Parkinson's Disease Drug Pipeline, data as of 8 Oct 2026. https://www.douglasinsights.com/pipeline/parkinsons-disease/